BR112016007386A2 - derivados alcalinos bicíclicos e usos dos mesmos - Google Patents
derivados alcalinos bicíclicos e usos dos mesmosInfo
- Publication number
- BR112016007386A2 BR112016007386A2 BR112016007386A BR112016007386A BR112016007386A2 BR 112016007386 A2 BR112016007386 A2 BR 112016007386A2 BR 112016007386 A BR112016007386 A BR 112016007386A BR 112016007386 A BR112016007386 A BR 112016007386A BR 112016007386 A2 BR112016007386 A2 BR 112016007386A2
- Authority
- BR
- Brazil
- Prior art keywords
- bicyclic
- alkaline derivatives
- alkaline
- derivatives
- bicyclic alkaline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1317545.0A GB2518873A (en) | 2013-10-03 | 2013-10-03 | Bicyclic alkyne derivatives and uses thereof |
| PCT/SG2014/000468 WO2015050505A1 (en) | 2013-10-03 | 2014-10-03 | Bicyclic alkyne derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016007386A2 true BR112016007386A2 (pt) | 2017-08-01 |
Family
ID=49630162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016007386A BR112016007386A2 (pt) | 2013-10-03 | 2014-10-03 | derivados alcalinos bicíclicos e usos dos mesmos |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9884867B2 (pt) |
| EP (1) | EP3052501B1 (pt) |
| JP (1) | JP6502332B2 (pt) |
| KR (1) | KR102329823B1 (pt) |
| CN (1) | CN105793262B (pt) |
| AU (1) | AU2014330089C1 (pt) |
| BR (1) | BR112016007386A2 (pt) |
| CA (1) | CA2926340A1 (pt) |
| GB (1) | GB2518873A (pt) |
| SG (1) | SG11201602579SA (pt) |
| WO (1) | WO2015050505A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2518873A (en) | 2013-10-03 | 2015-04-08 | Agency Science Tech & Res | Bicyclic alkyne derivatives and uses thereof |
| AU2017395023B2 (en) * | 2016-12-23 | 2022-04-07 | Plexxikon Inc. | Compounds and methods for CDK8 modulation and indications therefor |
| WO2019013703A1 (en) * | 2017-07-14 | 2019-01-17 | Agency For Science, Technology And Research (A*Star) | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| CN107641126A (zh) * | 2017-10-25 | 2018-01-30 | 上海道亦化工科技有限公司 | 一种基于咪唑并哒嗪的有机电致发光化合物及其用途和有机电致发光器件 |
| WO2020013531A1 (ko) * | 2018-07-10 | 2020-01-16 | 보로노이바이오 주식회사 | N-(3-(이미다조[1,2-b]피리다진-3-일에티닐)-4-메틸페닐)-5-페닐-4,5-다이하이드로-1H-피라졸-1-카복사마이드 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물 |
| WO2020046770A1 (en) * | 2018-08-31 | 2020-03-05 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Kinase activity in tumors |
| CN111978325B (zh) * | 2019-05-22 | 2023-11-17 | 中国药科大学 | 咪唑并哒嗪类mnk1/mnk2激酶抑制剂及其制备方法和应用 |
| CN111235163B (zh) * | 2020-03-20 | 2022-05-31 | 南京农业大学 | 水稻减数***发育相关基因OsMFS1及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1863818B1 (en) * | 2005-03-23 | 2010-03-10 | F.Hoffmann-La Roche Ag | Acetylenyl-pyrazolo-pvrimidine derivatives as mglur2 antagonists |
| WO2007013673A1 (en) | 2005-07-29 | 2007-02-01 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
| LT2495016T (lt) * | 2005-12-23 | 2020-02-10 | Ariad Pharmaceuticals, Inc. | Bicikliniai heteroarilų junginiai |
| SI1973545T1 (sl) * | 2005-12-23 | 2013-04-30 | Ariad Pharmaceuticals, Inc. | Spojine bicikličnega heteroarila |
| US20110046127A1 (en) * | 2007-11-08 | 2011-02-24 | Paolo Pevarello | Imidazopyridazines for Use as Protein Kinase Inhibitors |
| WO2010017047A1 (en) * | 2008-08-05 | 2010-02-11 | Merck & Co., Inc. | Therapeutic compounds |
| US9024021B2 (en) * | 2011-01-21 | 2015-05-05 | Sun Pharma Advanced Research Company Ltd. | Diarylacetylene hydrazide containing tyrosine kinase inhibitors |
| US20140066434A1 (en) * | 2011-04-07 | 2014-03-06 | Ariad Pharmaceuticals, Inc. | Methods and Compositions for Treating Parkinson's Disease |
| CN102584830A (zh) * | 2011-12-30 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 二氢化茚酰胺化合物、其药物组合物及其用途 |
| CN103214481B (zh) * | 2012-01-21 | 2016-08-03 | 中国科学院上海药物研究所 | 新型咪唑并[1,2-a]吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途 |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| US20150105377A1 (en) * | 2012-04-25 | 2015-04-16 | Ariad Pharmaceuticals, Inc. | Methods and Compositions for RAF Kinase Mediated Diseases |
| CN103421005A (zh) * | 2012-05-16 | 2013-12-04 | 上海医药集团股份有限公司 | 具有抗肿瘤活性的乙炔衍生物 |
| CN102775411A (zh) * | 2012-08-17 | 2012-11-14 | 浙江大德药业集团有限公司 | 作为蛋白激酶抑制剂的芳乙炔基苯甲酰胺类化合物 |
| GB2518873A (en) | 2013-10-03 | 2015-04-08 | Agency Science Tech & Res | Bicyclic alkyne derivatives and uses thereof |
-
2013
- 2013-10-03 GB GB1317545.0A patent/GB2518873A/en not_active Withdrawn
-
2014
- 2014-10-03 JP JP2016520055A patent/JP6502332B2/ja active Active
- 2014-10-03 US US15/026,955 patent/US9884867B2/en active Active
- 2014-10-03 BR BR112016007386A patent/BR112016007386A2/pt not_active Application Discontinuation
- 2014-10-03 CN CN201480065650.2A patent/CN105793262B/zh active Active
- 2014-10-03 WO PCT/SG2014/000468 patent/WO2015050505A1/en active Application Filing
- 2014-10-03 EP EP14851209.8A patent/EP3052501B1/en active Active
- 2014-10-03 KR KR1020167010484A patent/KR102329823B1/ko active IP Right Grant
- 2014-10-03 AU AU2014330089A patent/AU2014330089C1/en not_active Ceased
- 2014-10-03 SG SG11201602579SA patent/SG11201602579SA/en unknown
- 2014-10-03 CA CA2926340A patent/CA2926340A1/en not_active Abandoned
-
2017
- 2017-12-29 US US15/858,733 patent/US10544149B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016531899A (ja) | 2016-10-13 |
| SG11201602579SA (en) | 2016-04-28 |
| CA2926340A1 (en) | 2015-04-09 |
| JP6502332B2 (ja) | 2019-04-17 |
| EP3052501A4 (en) | 2017-03-29 |
| US10544149B2 (en) | 2020-01-28 |
| KR102329823B1 (ko) | 2021-11-22 |
| AU2014330089C1 (en) | 2019-06-20 |
| GB2518873A (en) | 2015-04-08 |
| AU2014330089A1 (en) | 2016-04-28 |
| US20180194771A1 (en) | 2018-07-12 |
| CN105793262B (zh) | 2019-09-03 |
| US9884867B2 (en) | 2018-02-06 |
| AU2014330089B2 (en) | 2018-12-13 |
| KR20160067873A (ko) | 2016-06-14 |
| WO2015050505A1 (en) | 2015-04-09 |
| EP3052501A1 (en) | 2016-08-10 |
| EP3052501B1 (en) | 2022-06-22 |
| CN105793262A (zh) | 2016-07-20 |
| US20160229860A1 (en) | 2016-08-11 |
| GB201317545D0 (en) | 2013-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2021012I1 (no) | avapritinib and pharmaceutically acceptable salts thereof | |
| CL2016000251A1 (es) | Anticuerpos anti-activina y usos de los mismos | |
| CL2016001241A1 (es) | Nuevos compuestos pesticidas y usos | |
| BR112016016289A2 (pt) | heteroaris e usos dos mesmos | |
| DK3010503T3 (da) | Hidtil ukendte bicykliske bromodomæne-inhibitorer | |
| DK3003039T3 (da) | Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser | |
| BR112016007386A2 (pt) | derivados alcalinos bicíclicos e usos dos mesmos | |
| BR112016013254A2 (pt) | Produto higiênico e produto absorvente | |
| DK3068505T3 (da) | Spillesystem og -fremgangsmåde | |
| CL2016001382A1 (es) | Estabilidad de gel mejorada | |
| ES2897680T8 (es) | Dispositivo de electroterapia | |
| BR112015007217A2 (pt) | compostos e usos do composto | |
| BR112015023621A2 (pt) | derivados de menopenem e usos dos mesmos | |
| DK2964623T3 (da) | Substituerede chroman-6-yloxycycloalkaner og deres anvendelse som farmaceutik | |
| FR3007291B1 (fr) | Composition cicatrisante et utlisation | |
| DE112014002295A5 (de) | Zerkleinerungsvorrichtung | |
| FI20145444A (fi) | Parvekerunko ja parveke | |
| ES1079133Y (es) | Caja fuerte | |
| FR3004417B1 (fr) | Pare battage | |
| TH1401007378A (th) | โคโพลิเมอร์ที่มีอะซีทิดิเนียมเป็นส่วนประกอบและการใช้โพลิเมอร์ดังกล่าว | |
| TH1401007245B (th) | ผลิตภัณฑ์ดูดซับ | |
| TH146512B (th) | ผลิตภัณฑ์ซึมซับ | |
| UA25711S (uk) | Серветка | |
| TH1501001602A (th) | อนุพันธ์ไบไซคลิกตัวใหม่ | |
| TH1501000327B (th) | สิ่งดูดซับ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |